Hong Seokchan, Kim Yong-Gil, Ahn Soo Min, Bae Seung-Hyeon, Lim Doo-Ho, Kim Jeong Kon, Lee Chang-Keun, Yoo Bin
Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Int J Rheum Dis. 2016 Dec;19(12):1317-1321. doi: 10.1111/1756-185X.12599. Epub 2015 Jul 29.
Hydronephrosis is a rare complication of systemic lupus erythematosus (SLE). Bladder and/or gastrointestinal involvement in SLE are associated with development of hydronephrosis, but the management and treatment outcomes of hydronephrosis are largely unknown. Therefore, we investigated the clinical manifestations and factors associated with the treatment response in patients with SLE complicated by hydronephrosis.
A retrospective analysis was performed of all 634 SLE patients who underwent computed tomography and/or ultrasonography between January 1998 and December 2013. We reviewed the clinical characteristics and treatment outcomes of patients with SLE-associated hydronephrosis.
Hydronephrosis was identified in 15 patients with SLE complicated by cystitis and/or enteritis. All patients were treated initially with moderate to high doses of corticosteroids. A follow-up imaging study showed that 11 (73.3%) of 15 patients experienced improvements in hydronephrosis, and urinary obstruction was resolved without urological intervention in the majority of these patients (8/11, 72.7%). The four patients who experienced no improvement in hydronephrosis were older than those who responded to treatment (median age [interquartile range]; 43.0 [37.5-53.0] years vs. 28.0 [21.0-38.5] years; P = 0.026). In addition, delayed treatment (≥ 1 month after onset of symptoms) with corticosteroids was more frequently observed in the non-responding patients than in the responding patients (P = 0.011).
Our findings suggest that treatment with corticosteroids alone leads to favorable outcomes in patients with SLE-associated hydronephrosis, except when treatment is delayed, particularly in elderly patients.
肾积水是系统性红斑狼疮(SLE)的一种罕见并发症。SLE患者膀胱和/或胃肠道受累与肾积水的发生有关,但肾积水的管理和治疗结果在很大程度上尚不清楚。因此,我们调查了SLE合并肾积水患者的临床表现及与治疗反应相关的因素。
对1998年1月至2013年12月期间接受计算机断层扫描和/或超声检查的634例SLE患者进行回顾性分析。我们回顾了SLE相关性肾积水患者的临床特征和治疗结果。
在15例合并膀胱炎和/或肠炎的SLE患者中发现了肾积水。所有患者最初均接受中至高剂量的糖皮质激素治疗。一项随访影像学研究显示,15例患者中有11例(73.3%)肾积水有所改善,并且在大多数这些患者中(8/11,72.7%)无需泌尿外科干预即可解决尿路梗阻问题。肾积水未改善的4例患者比治疗有反应的患者年龄更大(中位年龄[四分位间距];43.0[37.5 - 53.0]岁对28.0[21.0 - 38.5]岁;P = 0.026)。此外,未反应患者比反应患者更频繁地出现糖皮质激素延迟治疗(症状出现后≥1个月)(P = 0.011)。
我们的研究结果表明,对于SLE相关性肾积水患者,单独使用糖皮质激素治疗可取得良好效果,但治疗延迟时除外,尤其是老年患者。